Literature DB >> 8547526

The prevalence of Helicobacter pylori infection in different countries.

R E Pounder1, D Ng.   

Abstract

The prevalence of Helicobacter pylori infection in a community is related to three factors: firstly, the rate of acquisition of infection with H. pylori--that is, incidence; secondly, the rate of loss of the infection; thirdly, the prolonged persistence of the bacterium in the gastroduodenal mucosa between infection and eradication. Variation in the prevalence of H. pylori is dominated by the great differences between communities in the incidence of H. pylori infection during childhood. The countries of the world form two groups: Group One is made up of those where the majority of children become infected with H. pylori during childhood and chronic infection continues during adult life; in Group Two only a minority of children are infected during childhood, but the prevalence of infection rises in proportion to age during adult life. Understanding the ages at which people acquire infection with H. pylori is crucial to the interpretation of H. pylori prevalence data.

Entities:  

Mesh:

Year:  1995        PMID: 8547526

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  148 in total

1.  Supra-angular biopsy is more reliable for atrophy recognization: analysis of 1598 cases for gastric mucosal histological examination.

Authors:  Ya-Li Zhang; Zhuo-Sheng Lai; Dian-Yuan Zhou; Nobutaka Yamada; Min Wen
Journal:  World J Gastroenterol       Date:  2000-12       Impact factor: 5.742

Review 2.  Association of Helicobacter pylori with Chronic Kidney Diseases: A Meta-Analysis.

Authors:  Karn Wijarnpreecha; Charat Thongprayoon; Pitchaphon Nissaisorakarn; Veeravich Jaruvongvanich; Kiran Nakkala; Ridhmi Rajapakse; Wisit Cheungpasitporn
Journal:  Dig Dis Sci       Date:  2017-03-06       Impact factor: 3.199

3.  Distinctive aspects of peptic ulcer disease, Dieulafoy's lesion, and Mallory-Weiss syndrome in patients with advanced alcoholic liver disease or cirrhosis.

Authors:  Borko Nojkov; Mitchell S Cappell
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 4.  Nontraditional therapies to treat Helicobacter pylori infection.

Authors:  Morris O Makobongo; Jeremy J Gilbreath; D Scott Merrell
Journal:  J Microbiol       Date:  2014-03-29       Impact factor: 3.422

5.  Genotypic and phenotypic stability of Helicobacter pylori markers in a nine-year follow-up study of patients with noneradicated infection.

Authors:  Anders Gustavsson; Magnus Unemo; Björn Blomberg; Dan Danielsson
Journal:  Dig Dis Sci       Date:  2005-02       Impact factor: 3.199

6.  Helicobacter pylori disrupts STAT1-mediated gamma interferon-induced signal transduction in epithelial cells.

Authors:  David J Mitchell; Hien Q Huynh; Peter J M Ceponis; Nicola L Jones; Philip M Sherman
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

7.  Helicobacter pylori infection in pregnant women from a U.S.-Mexico border population.

Authors:  Karen J Goodman; Kathleen O'Rourke; R Sue Day; Constance Wang; Thomas Redlinger; Armando Campos; Jose Manuel de la Rosa
Journal:  J Immigr Health       Date:  2003-07

8.  Do we eradicate Helicobacter pylori in hospitalized patients with peptic ulcer disease?

Authors:  Frank Wong; George Ou; Sigrid Svarta; Ricky Kwok; Kieran Donaldson; Joe Frenette; Robert Enns
Journal:  Can J Gastroenterol       Date:  2013-09-13       Impact factor: 3.522

9.  The association of drinking water quality and sewage disposal with Helicobacter pylori incidence in infants: the potential role of water-borne transmission.

Authors:  Penny B Travis; Karen J Goodman; Kathleen M O'Rourke; Frank D Groves; Debajyoti Sinha; Joyce S Nicholas; Jim VanDerslice; Daniel Lackland; Kristina D Mena
Journal:  J Water Health       Date:  2010-03       Impact factor: 1.744

10.  Is Helicobacter pylori infection a risk factor for disease severity in systemic sclerosis?

Authors:  Mislav Radić; Dušanka Martinović Kaliterna; Damir Bonacin; Jadranka Morović Vergles; Josipa Radić; Damir Fabijanić; Vedran Kovačić
Journal:  Rheumatol Int       Date:  2012-12-06       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.